In the past decade, substantial advances have been made in understanding the biology of
tumour-associated macrophages (TAMs), and their clinical relevance is emerging. A …

The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …

The response rate of pancreatic cancer to chemotherapy or immunotherapy pancreatic
cancer is low. Although minimally invasive irreversible electroporation (IRE) ablation is a …

Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising
cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most …

Abstract Background Dendritic cells (DCs) mediate divergent immune effects by activating T
cells or negatively regulating the immune response to promote immune tolerance. They …

Intravesical administration of first‐line drugs has shown failure in the treatment of bladder
cancer owing to the poor tumor retention time of chemotherapeutics. Herein, we report an …

Simple Summary Tumor-associated macrophages (TAMs) play major roles in solid tumor
development. They can have both anti-tumor and pro-tumor properties depending on their …

Targeted immunomodulation through biomolecule‐based nanostructures, especially to
dendritic cells (DCs), holds great promise for effective cancer therapy. However, construction …

The clinical use of anti-CD40 agonist monoclonal antibodies (mAbs) is aimed at recruiting
the immune system to fight the tumor cells. This approach has been demonstrated to be …

While anti-CD47 antibodies hold promise for cancer immunotherapy, early-phase clinical
trials have shown limited clinical benefit, suggesting that CD47 blockade alone might be …